⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2277077 | 0.96 | — | — | |
| SCHEMBL1072552 | 0.93 | CHRNB2 (0.34) | — | |
| Hydrochloric Acid SCHEMBL1238902 | 0.90 | CHRNB2 (0.33) | — | |
| SCHEMBL24439048 | 0.83 | — | — | |
| SCHEMBL3295583 | 0.83 | — | — | |
| SCHEMBL12862665 | 0.83 | — | — | |
| SCHEMBL13598562 | 0.83 | — | — | |
| SCHEMBL13645939 | 0.76 | — | — | |
| SCHEMBL4146707 | 0.76 | — | — | |
| SCHEMBL245466 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | claimed |
| EP-4705300-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | claimed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | claimed |
| EP-2991978-B1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F HOFFMANN LA ROCHE SA (CH) | 2025-08-20 | — | — | EP | claimed |
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | claimed |
| WO-2025008059-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | claimed |
| CN-119255997-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2025-01-03 | — | — | CN | claimed |
| US-RE47848-E1 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2020-02-11 | — | — | US | claimed |
| US-10028954-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | claimed |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | claimed |
| US-20180117044-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | claimed |
| US-20170239246-A9 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-08-24 | — | — | US | claimed |
| US-20160158234-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | claimed |
| EP-2991978-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche SA (CH) | 2016-03-09 | — | — | EP | claimed |
| US-9266862-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2016-02-23 | — | — | US | claimed |
| WO-2014177060-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | claimed |
| US-20140328805-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | claimed |